Established thrombotic risk factors commonly present in semaglutide users include: Obesity (BMI 30 kg/m), which increases VTE risk 2-3 fold [13] Type 2 diabetes and insulin resistance Prolonged immobility or sedentary lifestyle History of previous blood clots Active cancer or recent cancer treatment Recent surgery, particularly orthopedic or abdominal procedures Smoking Certain medications, including estrogen-containing contraceptives or hormone replacement therapy Inherited thrombophilias (clotting disorders) Advanced age (risk increases after age 60) Pregnancy and postpartum period (note that semaglutide should be discontinued when pregnancy is recognized) Patients initiating semaglutide should undergo comprehensive baseline assessment including medical history review, with particular attention to prior thrombotic events and family history of clotting disorders
These tablets are formulated with high-
Contact your GP, diabetes specialist nurse, or NHS 111 if: Headaches are persistent, worsening, or significantly impacting daily activities despite simple management measures You experience frequent hypoglycaemic episodes (blood glucose below 4 mmol/L) [31] [32] You have signs of dehydration such as reduced urine output, excessive thirst, or dizziness when standing Side effects are affecting medication adherence or quality of life You develop new or unusual symptoms that concern you Headaches follow a different pattern from any pre-existing headache disorder Healthcare professionals can assess whether headaches are likely related to GLP-1 therapy or require investigation for alternative causes
For patients who are reluctant to add daily injections to their routine, GHK-Cu may not be the right fit regardless of its other benefits
It may also be feasible to eliminate this hurdle by reducing the resistance (Sadoughi et al., 2022)
Carry a sanitizer around to kill the germs immediately after contact and avoid infection
